- Home
- SLNO
as 03-28-2025 4:00pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 2.3B | IPO Year: | 2014 |
| Target Price: | $92.00 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $36.61 - $73.97 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Jan 2 '25 | Sell | $45.82 | 7,874 | $360,460.44 | 115,410 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Jan 2 '25 | Sell | $45.82 | 21,091 | $965,515.52 | 709,476 | |
| Yen Kristen | SLNO | SEE REMARKS | Jan 2 '25 | Sell | $45.82 | 4,860 | $222,483.86 | 78,945 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Jan 2 '25 | Sell | $45.82 | 3,030 | $138,709.47 | 107,485 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Investor's Business Daily
a day ago
Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, Pulling Aardvark Higher
MT Newswires
a day ago
Sector Update: Health Care Stocks Flat to Higher Premarket Thursday
MT Newswires
a day ago
Sector Update: Health Care
MT Newswires
a day ago
Top Premarket Gainers
MT Newswires
a day ago
Update: Soleno Therapeutics Secures FDA Approval for Hyperphagia Treatment; Shares Surge Premarket
MT Newswires
2 days ago
Soleno Therapeutics Secures FDA Approval for Drug to Treat Hyperphagia
GlobeNewswire
2 days ago
Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome
BioPharma Dive
2 days ago
First Prader-Willi drug to reduce hunger approved by FDA
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.